Surgical Treatment of Macular Hole without Postoperative Vitreous Cavity Tamponade
https://doi.org/10.18008/1816-5095-2019-4-449-453
Abstract
Purpose. To present the technique of macular hole surgery without vitreous cavity tamponade with gas or another vitreous substitute in post-op period.
Patients and Methods. Frequency of the disease is 3 cases per 10,000, more often after 55 years — 3–3.3 cases per 1000, and the peak occurs at the age of 60 years and older. According to current data, the frequency of closure MH after vitreous surgery varies from 68 to 98 %. Sixteen eyes of 16 patients were operated on for full-thickness macular holes 100 to 932 (558.5 ± 50.9) microns in diameter. BCVA was 0.04 to 0.2 (0.09 ± 0.01). Follow-up period of the patients was 9 ± 6.3 weeks.
Results. No intraoperative and postoperative complications were seen. In the result of surgery complete closure of the macular hole and anatomical restoration of the macula was achieved in 15 of 16 cases (92.8%). Postoperative BCVA was 0.2 to 0.6 (0.4 ± 0.04). A recurrence in one case was associated with a violation of operation technology when a partial mechanical displacement of the fibrin film with a cannula during PFCL exchange for air occurred.
Conclusions. The suggested method of macular hole surgery without postoperative tamponade of the vitreous cavity with gas or another vitreous substitute may be used in routine clinical practice: Without face down positioning, reduced risk of cataract and increased IOP, air flight and climb to a height in the early post-op period.
About the Authors
V. N. Kazaykin
IRTC Eye Microsurgery Ekaterinburg Center
Russian Federation
Russian Federation
MD, head of vitreoretinal department
A. Bardina str., 4A, Ekaterinburg, 620149, Russian Federation
A. U. Kleymenov
IRTC Eye Microsurgery Ekaterinburg Center
Russian Federation
Russian Federation
Ophthalmologist
A. Bardina str.,. 4A, Ekaterinburg, 620149, Russian Federation
A. V. Lizunov
IRTC Eye Microsurgery Ekaterinburg Center
Russian Federation
Russian Federation
Ophthalmologist
A. Bardina str.,. 4A, Ekaterinburg, 620149, Russian Federation
References
1. Bikbov M.M., Fajzrahmanov R.R. Influence of antivasoprolipherative therapy on morphological and functional features classic choroidal neovascularization in patients with age‑related macular degeneration. Vestnik of russian military medical academy = Vestnik Rossiiskoi voenno-meditsinskoi akademii. 2016;54(2):111–115 (In Russ.)
2. Kelly N.E., Wendel R.T. Vitreous surgery for idiopathic macular holes. Results of a pilot study. Arch Ophthalmol. 1991;109(5):654–659. DOI: 10.1097/00006982‑199111040‑00026
3. Ezra E., Gregor Z.J. Surgery for idiopathic full‑thickness macular hole: two‑year results of a randomized clinical trial comparing natural history, vitrectomy, and vitrectomy plus autologous serum: Morfields Macular Hole Study Group RAeport no 1. Arch Ophthalmol. 2004;122(2):224–236. DOI: 10.1097/01.ieb.0000142782.97667.fc
4. Gass J.D.M. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol. 1995;119(6):752–759. DOI: 10.1016/s0002‑9394(14)72781‑3
5. Casuso L.A., Scott I.U., Flynn H.W. Jr., Gass J.D., Smiddy W.E., Lewis M.L., Schiffman J. Long‑term follow‑up of unoperated macular holes. Ophthalmology. 2001;108:1150–1155.
6. Unsal E., Cubuk M.O., Ciftci F. Preoperative prognostic factors for macular hole surgery: Which is better? Oman J Ophthalmol. 2019 Jan‑Apr;12(1):20–24. DOI: 10.4103/ojo.ojo_247_2017
7. Christensen U.C., Kroyer K., Sander B., Larsen M., Henning V., Villumsen J., la Cour M. Value of internal limiting membrane peeling in surgery for idiopathic macular hole stage 2 and 3: a randomised clinical trial. Br J Ophthalmol. 2009;93(8):1005–1015. DOI: 10.1136/bjo.2008.151266
8. Al Sabti K., Kumar N., Azad R.V. Extended internal limiting membrane peeling in the management of unusually large macular holes. Ophthalmic Surg Lasers Imaging. 2009;40(2):185–187. DOI: 10.3928/15428877‑20090301‑03
9. Samojlov A.N., Hajbrahmanov T.R, Fazleeva G.A, Samojlova P.A. Idiopathic macular hole: history and status quo review. Annals of Ophthalmology = Vestnik oftal’mologii. 2017;133(6):131–137 (In Russ.). DOI: 10.17116/oftalma20171336131‑137
10. Bikbov M.M., Fajzrahmanov R.R., Kalanov M.R. Clinical and functional assessment of the effectiveness of combined vitreoretinal intervention in proliferative diabetic retinopathy. Saratov Journal of Medical Scientific Research = Saratovskii nauchno-meditsinskii zhurnal. 2017;13(2):338–345 (In Russ.)
11. Olsen T.W., Sternberg P. Jr, Capone A. Jr, Martin D.F., Lim J.I., Grossniklaus H.E., Aaberg T.M. Sr. Macular hole surgery using thrombin‑activated fibrinogen and selective removal of the internal limiting membrane. Retina. 1998;18(4):322–329. DOI: 10.1097/00006982‑199919050‑00031
12. Liggett P.E., Skolik D.S., Horio B., Saito Y., Alfaro V., Mieler W. Human autologous serum for the treatment of full‑thickness macular holes. A preliminary study. Ophthalmology. 1995;102(7):1071–1076. DOI: 10.1016/s0161‑6420 (95)30909‑8
13. Hoerauf H., Kluter H., Joachimmeyer E., Roider J., Framme C., Schlenke P., Kirchner H., Lagua H. Results of vitrectomy and the no‑touch‑technique using autologous adjuvants in macular hole treatment. Int Ophthalmol. 2001;24(3):151–159. DOI: 10.1023/a:1021566806836
14. Gaudric A., Massin P., Paques M., Santiago P.‑Y., Guez J.‑E., Le Gargasson J.‑F., Mundler O., Drouet L. Autologous platelet concentrate for the treatment of full‑thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995;233(9):549–554. DOI: 10.1007/bf00404704
15. Paques M., Chastang C., Mathis A., Sahel J., Massin P., Dosquet C., Korobelnik J.F., Le Gargasson J.F., Gaudric A. Effect of autologous platelet concentrate in surgery for idiopathic macular hole: results of a multicenter, double‑masked, randomized trial. Platelets in Macular Hole Surgery Group. Ophthalmology. 1999;106(5):932–938. DOI: 10.1016/s0161‑6420(99)00512‑6
16. Konstantinidis A., Hero M., Nanos P., Panos G.D. Efficacy of autologous platelets in macular hole surgery, Clin Ophthalmol. 2013(7):745–750. DOI: 10.2147/opth.s44440
17. Kleymenov A.Yu., Kazaykin V.N. A method for the surgical treatment of macular rupture with intraoperative use of an organofluorine compound. Patent RU 2685648, 04.05.18 Accessed 01.07.2019 (In Russ.)
Review
For citations:
Kazaykin V.N., Kleymenov A.U., Lizunov A.V. Surgical Treatment of Macular Hole without Postoperative Vitreous Cavity Tamponade. Ophthalmology in Russia. 2019;16(4):449-453. (In Russ.) https://doi.org/10.18008/1816-5095-2019-4-449-453
Views:
1772
Email this article 